CD44 and breast cancer: To validate the involvement of the PI3K/Akt signaling in the TMX resistance in BC cells, the T47D-FOXD3-AS1 and MCF7-FOXD3-AS1 cells were treated with a PI3K/Akt-specific antagonist PI3K-IN-1, and cells treated with DMSO were set as the control.